Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
7shRNA-modified autologous hematopoietic stem cells
- Development stage
- Unknown
- Lead developer
- Hangzhou First People's Hospital
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, Stem Cell Therapies → Cell Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
7shRNA-modified autologous hematopoietic stem cells is an experimental cell and gene therapy being developed for the treatment of HIV infection complicated by lymphoma. The therapy involves the extraction of a patient's own hematopoietic stem cells, which are then genetically modified using a lentiviral vector to stably express seven distinct short hairpin RNAs (7shRNA). These shRNAs are designed to target multiple conserved regions of the HIV-1 genome to inhibit viral replication and prevent the infection of new cells. The modified cells are then transplanted back into the patient following chemotherapy. This approach aims to provide a functional cure for HIV by creating a reservoir of HIV-resistant immune cells while simultaneously treating the underlying lymphoma through autologous stem cell transplantation.
- Other names
- 7shRNA-Modified Autologous Stem Cell Transplantation7shRNA-modified autologous stem cells
02
Targets
HIV-1 RNA (HIV-1 RNA genome)
Beyond the preview
Go deeper on 7shRNA-modified autologous hematopoietic stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 7shRNA-modified autologous hematopoietic stem cells.